With plenty of GLP-1 money to spend, Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for ...

Diaylsis-technology maker Fresenius Medical Care could end up benefiting from blockbuster obesity drugs, according to its chief executive, contrary to concerns that such treatments could deplete ...

Recent health headlines spotlight Surgery Partners rejecting Bain Capital's offer, the U.S. betting on China's drug potential ...

Aldeyra has resubmitted its new drug application for reproxalap, an investigational dry eye treatment, which contained new ...

Sarepta Therapeutics (NasdaqGS:SRPT) recently announced that its SRP-9003 gene therapy received a platform technology designation from the FDA, and updated safety protocols for ELEVIDYS in the UK.

The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.

Eli Lilly is buying Verve Therapeutics, developer of gene-editing treatments for cardiovascular disease, for $1 billion plus ...

For the second time, a person with DMD has died of acute liver failure after being treated with the one-time gene therapy Elevidys.

The pending deal was rumored overnight after a report from the Financial Times, spurring analysts to speculate that if true, ...

Shares of ReNew Energy Global Plc RNW rose 4% after reporting fourth-quarter fiscal 2025 earnings of 10 cents/share, beating the Zacks Consensus Estimate of 7 cents. Shares of Northrop Grumman ...

Stock market futures are up slightly. Enthusiasm has been tempered by geopolitical risks and uncertainty ahead of Wednesday’s Federal Reserve decision. The Fed is widely expected to hold rates steady, ...

Verve Therapeutics stock nearly doubled Tuesday after Eli Lilly agreed to buy the gene-editing company for up to $1.3 billion ...